Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 538-548

  Ebert, Ulrike ^a   Oertel, Reinhard ^b   Kirch, Wilhelm ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUMAZENIL; MIDAZOLAM; PHYSOSTIGMINE; PLACEBO;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROENCEPHALOGRAM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION;

EID: 0034128412     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.105988     Document Type: Article

References (47)

1. 1. Breimer LT, Hennis PJ, Bovill JG, Spierdijk J. The efficacy of flumazenil versus physostigmine after midazolam-alfentanil anaesthesia in man. Eur J Anaesthesiol Suppl 1988;2:109-16.
2. 2. Piekarsky JM, Rossmann JA, Putman J. Benzodiazepine reversal with flumazenil - a review of the literature. J Can Dent Assoc 1992;58:307-10.
3. 3. Bonfiglio MF, Fisher-Katz LE, Saltis LM, Traeger SM, Martin BR, Nackes NA, et al. A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline. Pharmacotherapy 1996;16:1166-72.
4. 4. Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992;23:191-215.
5. 5. Sadzot B, Frost JJ. Benzodiazepine receptors. In: Frost JJ, Wagner HN Jr, editors. Quantitative imaging: neuroreceptors, neurotransmitters, and enzymes. New York: Raven Press; 1990. p. 109-27.
6. 6. Consolo S, Garattini S, Ladinsky H. Actions of benzodiazepines on the cholinergic system. In: Costa E, Greengard P, editors. Mechanism of action of benzodiazepines. New York: Raven Press; 1975. p. 63-80.
7. 7. Davies J, Polc P. Effect of a water-soluble benzodiazepine on the response of spinal neurones to acetylcholine and excitatory amino acid analogues. Neuropharmacology 1978;17:217-20.
8. 8. Vatashsky E, Beilin B, Razin M, Weinstock M. Mechanism of antagonism by physostigmine of acute flunitrazepam intoxication. Anesthesiology 1986;64:248-52.
9. 9. Nilsson E, Himberg JJ. Physostigmine for post-operative somnolence after diazepam-nitrous oxide anaesthesia. Acta Anaesthesiol Scand 1982;26:9-14.
10. 10. Bidwai AV, Stanley TH, Rogers C, Riet EK. Reversal of diazepam-induced postanesthetic somnolence with physostigmine. Anesthesiology 1979;51:256-9.
11. 11. Caldwell CB, Gross JB. Physostigmine reversal of midazolam-induced sedation. Anesthesiology 1982;57: 125-7.
12. 12. Larson GF, Hurlbert BJ, Wingard DW. Physostigmine reversal of diazepam-induced depression. Anesth Analg 1977;56:348-51.
13. 13. Vorsanger GJ, Roberts JT. Midazolam-induced athetoid movements of the lower extremities during epidural anesthesia reversed by physostigmine. J Clin Anesth 1993;5: 494-6.
14. 14. Garber JG, Ominsky AJ, Orkin FK, Quinn P. Physostigmine-atropine solution fails to reverse diazepam sedation. Anesth Analg 1980;59:58-60.
15. 15. Pandit UA, Kothary SP, Samra SK, Domino EF, Pandit SK. Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam. Anesth Analg 1983;62: 679-85.
16. 16. Greenblatt DJ, Ehrenberg BL, Gunderman J, Locniskar A, Scavone JM, Harmatz JS et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989;45: 356-65.
17. 17. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the CNS effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-28.
18. 18. Fiset P, Lemmens HLM, Egan TE, Shafer SL, Stanski DR. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin Pharmacol Ther 1995; 58:567-82.
19. 19. Spencer EM, Green JL, Willatts SM. Continuous monitoring of depth of sedation by EEC spectral analysis in patients requiring mechanical ventilation. Br J Anaesth 1994;73:649-54.
20. 20. Wolff J, Carl P, Clausen TG, Mikkelsen BO. Ro 15-1788 for postoperative recovery: a randomised clinical trial in patients undergoing minor surgical procedures under midazolam anaesthesia. Anaesthesia 1986;41:1001-6.
21. 21. Chang AC, Solinger MA, Yang DT, Chen YK. Impact of flumazenil on recovery after outpatient endoscopy: a placebo-controlled trial. Gastrointest Endosc 1999;49: 573-9.
22. 22. Jasper HH. The ten-twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 1958;10:371-5.
23. 23. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998;38:720-6.
24. 24. Herrmann WM, Kubicki St, Künkel H, Kugler J, Lehmann D, Maurer K, et al. Recommendations of the Deutsche EEG-Gesellschaft for the mapping of EEG parameters [in German]. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte 1989;20:125-32.
25. 25. Bührer M, Maitre PO, Hung O, Stanski DR. Electroencephalographic effects of benzodiazepines; I: choosing an electroencephalographic parameter to measure the effect of midazolam on the central nervous system. Clin Pharmacol Ther 1990;48:544-54.
26. 26. Breimer LT, Hennis PJ, Burm AC, Danhof M, Bovill JG, Spierdijk J, et al. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers: pharmacokinetic/pharmacodynamic modelling. Clin Pharmacokinet 1990;18:245-53.
27. 27. van Steveninck AL, Mandema JW, Tuk B, van Dijk JG, Schoemaker HC, Danhof M, et al. A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br J Clin Pharmacol 1993;36:109-15.
28. 28. Tuk B, Herben VM, Mandema JW, Danhof M. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J Pharmacol Exp Ther 1998;284:202-7.
29. 29. Engelhardt W, Friess K, Hartung E, Sold M, Dierks T. EEG and auditory evoked potential P300 compared with psychometric tests in assessing vigilance after benzodiazepine sedation and antagonism. Br J Anaesth 1992;69: 75-80.
30. 30. Koopmans R, Dingemanse J, Danhof M, Horsten GP, van Boxtel CJ. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther 1988;44:14-22.
31. 31. Veselis RA, Reinsel R, Alagesan R, Heino R, Bedford RF. The EEG as a monitor of midazolam amnesia: changes in power and topography as a function of amnestic state. Anesthesiology 1991;74:866-74.
32. 32. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;80:1-46.
33. 33. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982. p. 409-24.
34. 34. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982;16:143-66.
35. 35. Schnider TW, Minto CF, Stanski DR. The effect compartment concept in pharmacodynamic modelling. Anaesth Pharmacol Rev 1994;2:204-13.
36. 36. Phillis JW, Bender AS, Wu PH. Benzodiazepines inhibit adenosine uptake into rat brain synaptosomes. Brain Res 1980;195:494-9.
37. 37. Phillis JW, Siemens RK, Wu PH. Effects of diazepam on adenosine and acetylcholine release from rat cerebral cortex: further evidence for a purinergic mechanism in action of diazepam. Br J Pharmacol 1980;70:341-8.
38. 38. Hussey HM. Physostigmine: value in treatment of central toxic effects of anticholinergic drugs [editorial]. JAMA 1975;231:1066.
39. 39. Heiser JF, Wilbert DE. Reversal of delirium induced by tricyclic antidepressant drugs with physostigmine. Am J Psychiatry 1974;131:1275-7.
40. 40. Sannita WG, Balestra V, DiBon G, Marotta V, Rosadini G. Human flash-VEP and quantitative EEG are independently affected by acute scopolamine. Electroencephalogr Clin Neurophysiol 1993;86:275-82.
41. 41. Sloan EP, Fenton GW, Standage KP. Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potentials, and verbal memory. Biol Psychiatry 1992;31:600-6.
42. 42. Klotz U, Ziegler G, Ludwig L, Reimann IW. Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol 1985;25:400-6.
43. 43. Gath I, Weidenfeld J, Collins GI, Hadad H. Electrophysiological aspects of benzodiazepine antagonists, Ro 15-1788 and Ro 15-3505. Br J Clin Pharmacol 1984;18: 541-7.
44. 44. Breimer LT, Burm AG, Danhof M, Hennis PJ, Vletter AA, de Voogt JW, et al. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991;20:497-508.
45. 45. Niedermeyer E. The normal EEG of the waking adult. In: Niedermeyer E, da Silva FL, editors. Electroencephalography: basic principles, clinical applications, and related fields. Baltimore: Williams and Wilkins; 1999. p. 149-73.
46. 46. Brown CR, Sarnquist FH, Canup CA, Pedley TA. Clinical, electroencephalographic, and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate. Anesthesiology 1979;50:467-70.
47. 47. Billard V, Gambus PL, Chamoun N, Stanski DR, Shafer SL. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Clin Pharmacol Ther 1997; 61:45-58.